AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer

Shots:

  • The companies collaborated to evaluate the use of immunoSEQ T-MAP, for which Adaptive will receive quarterly payments + sequencing and data mapping fees
  • AstraZeneca to provide cancer patients’ biological samples while Adaptive will sequence the samples & deliver TCR-antigen mapping data using its clinical immunomics database of 58B+ immune cell receptors and antigens
  • AstraZeneca gets an option to enter into an agreement with Adaptive for the development & commercialization of a CDx or therapeutic application based on T-MAP data. ImmunoSEQ T-MAP combines the sequencing and mapping capabilities of Adaptive to map TCRs to antigens, across AZ’s oncology portfolio

Click here ­to­ read full press release/ article | Ref: Adaptive | Image: Glassdoor

The post AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer first appeared on PharmaShots.

PharmaShots Weekly Snapshot (Jan 4-8, 2020)

Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies

Published: Jan 7, 2020 | Tags: Almirall, Tyris, Collaborate, Develop, Next Generation, Gene Therapies

Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1 of Study 102 for DMD   

Published: Jan 7, 2020 | Tags: Sarepta, Reports, Mixed Results, SRP-9001, (rAAVrh74.MHCK7.micro-dystrophin), Part 1, Study 102, DMD

PerkinElmer to Acquire Oxford Immunotec for ~$591M

Published: Jan 7, 2020 | Tags: PerkinElmer, Acquire, Oxford Immunotec, ~$591M

Pfizer Reports the First Patients Dosing of PF-06939926 in P-III CIFFREO Study for DMD

Published: Jan 7, 2020 | Tags: Pfizer, Reports, First, Patients, Dosing, of PF-06939926 in P-III CIFFREO Study for DMD

Alnylam Reports Results of Vutrisiran in P-III HELIOS-A Study for Patients with hATTR Amyloidosis with Polyneuropathy

Published: Jan 7, 2020 | Tags: Alnylam, Reports, Results, Vutrisiran, P-III, HELIOS-A, Study, Patients, hATTR Amyloidosis, Polyneuropathy

Bayer Collaborates with CureVac for CVnCoV Against COVID-19

Published: Jan 7, 2020 | Tags: Bayer, Collaborates, CureVac, CVnCoV, Against, COVID-19

Hologic to Acquire Biotheranostics for ~$230M

Published: Jan 7, 2020 | Tags: Hologic, Acquire, Biotheranostics, ~$230M

Pfizer Signs a License and Supply Agreement with ImaginAb for CD8 ImmunoPET Technology

Published: Jan 6, 2020 | Tags: Pfizer, Signs, License, Supply, Agreement, ImaginAb, CD8 ImmunoPET Technology

Merck KGaA Acquires AmpTec to Strengthen its mRNA Capabilities for Vaccines, Treatments and Diagnostics

Published: Jan 6, 2020 | Tags: Merck KGaA, Acquires, AmpTec, Strengthen, mRNA, Capabilities,  Vaccines, Treatments, Diagnostics

Genentech Signs ~$1B Pact with Ribometrix to Develop RNA-Targeted Small Molecule Therapies

Published: Jan 6, 2020 | Tags: Genentech, Signs, ~$1B, Pact, Ribometrix, Develop, RNA-Targeted, Small Molecule Therapies

Astellas Reports the US FDA’s Acceptance of Priority Review for its NDO Therapy

Published: Jan 6, 2020 | Tags: Astellas, Reports, US, FDA, Acceptance, Priority Review, NDO Therapy, Myrbetriq, mirabegron, tablets, oral suspension

Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

Published: Jan 6, 2020 | Tags: Pfizer, Collaborates, Dewpoint, Develop, Therapies, Rare Form of Muscular Dystrophy

 Nirmidas Receives the US FDA’s EUA for its COVID-19 Rapid Antibody Fingerstick Test    

Published: Jan 6, 2020 | Tags: Nirmidas, Receives, US, FDA, EUA, COVID-19, Rapid, Antibody, Fingerstick Test

AstraZeneca’s Farxiga (dapagliflozin) Receives the US FDA’s Priority Review for Chronic Kidney Disease

Published: Jan 6, 2020 | Tags: AstraZeneca, Farxiga, (dapagliflozin), Receives, US, FDA, Priority Review, Chronic Kidney Disease

AbbVie Reports Results of Skyrizi (Risankizumab) in P-III Studies for Active Psoriatic Arthritis

Published: Jan 5, 2020 | Tags: AbbVie, Reports, Results, Skyrizi, (Risankizumab), P-III, Studies, Active Psoriatic Arthritis

Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

Published: Jan 5, 2020 | Tags: Regenxbio, Provide, Update, RGX-314, Treat, Wet AMD, RGX-202

Evotec Receives Milestones in its Neurodegeneration Collaboration with BMS

Published: Jan 5, 2020 | Tags: Evotec, Bristol Myers Squibb, $6M, Milestones

Stryker Acquires OrthoSensor and its Knee Surgery Sensor Technology

Published: Jan 5, 2020 | Tags: Stryker, Acquires, OrthoSensor, Knee Surgery Sensor Technology

Biogen Signs a License Agreement with ViGeneron for Ophthalmic Gene Therapy Development

Published: Jan 4, 2020 | Tags: ViGeneron, Signs, Global License Agreement, Biogen, Ophthalmic Gene Therapy, Development

 Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China

Published: Jan 4, 2020 | Tags: Y-Biologics, signed, License Agreement, 3D Medicines, Develop, Manufacture, Commercialize, YBL-013

aTyr Reports Results of ATYR1923 in P-ll Study for COVID-19 Patients with Severe Respiratory Complications

Published: Jan 4, 2020 | Tags: aTyr Pharma, Report, Positive Results, ATYR1923, P-ll Study, COVID-19

Genentech’s Tiragolumab + Tecentriq Receive the US FDA’s Breakthrough Therapy Designation for PD-L1-High Non-Small Cell Lung Cancer

Published: Jan 5, 2020 | Tags: Genentech, Tiragolumab + Tecentriq, Receives, US FDA’s, Breakthrough Therapy Designation, PD-L1-High Non-Small Cell Lung Cancer

Pfizer and OPKO Reports the US FDA’s Acceptance of BLA for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

Published: Jan 4, 2020 | Tags: Pfizer, OPKO, Reports, US FDA, Acceptance, BLA, Somatrogon, Treat, Growth Hormone Deficiency (GHD)

 Hologic to Acquire Somatex for ~$64 M   

Published: Jan 4, 2020 | Tags: Hologic, Acquire, Somatex, $64 M

Provention Bio Reports Submission of BLA and Priority Review to the US FDA for Teplizumab to Prevent T1D  

Published: Jan 3, 2020 | Tags: Provention Bio, Reports, Submission, BLA, Priority Review, US, FDA, Teplizumab, Prevent, T1D

Oura Ring Monitors Body Temperature and Identify Early COVID-19 Symptoms

Published: Jan 2, 2020 | Tags: Oura Ring Monitors, Body Temperature, Identify, Early, COVID-19, Symptoms

Tiziana Completes Clinical Trial of Nasally Administered Foralumab for COVID-19 in Brazil

Published: Jan 3, 2020 | Tags: Tiziana, Completes, Clinical Trial, Nasally, Administered, Foralumab, COVID-19, Brazil

 Antengene Reports NDA Submission for ATG-010 (Selinexor) to Treat RRMM and RR DLBCL in South Korea     

Published: Jan 3, 2020 | Tags: Antengene, Reports, NDA, Submission, ATG-010, (Selinexor), RRMM, RR DLBCL, South Korea

AstraZeneca’s COVISHIELD Receives EUA in India for COVID-19

Published: Jan 4, 2020 | Tags: AstraZeneca, COVISHIELD, Receives, EUA in India

RedHill Reports Results of Yeliva (opaganib) in P-II Study for COVID-19

Published: Jan 3, 2020| Tags: RedHill, Reports, Results, Yeliva, (opaganib), P-II, Study, COVID-19

Related Post: PharmaShots Weekly Snapshots (Dec 28- 31, 2020)

The post PharmaShots Weekly Snapshot (Jan 4-8, 2020) first appeared on PharmaShots.

Bayer Collaborates with CureVac for CVnCoV Against COVID-19

Shots:

  • Bayer to support the development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate, CVnCoV and will contribute its expertise and established infrastructure in numerous area
  • Curevac will be the MAH for the product while Bayer will support CureVac with country operations within the EU and additional markets. Additionally, Bayer has an option to MAH outside the EU
  • The companies plan to combine their strengths for CureVac to be in a position to supply hundreds of millions of CVnCoV doses across the globe

Click here ­to­ read full press release/ article | Ref: Bayer | Image: GMPNews

The post Bayer Collaborates with CureVac for CVnCoV Against COVID-19 first appeared on PharmaShots.

Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

Shots:

  • Dewpoint to receive up front payment and up to $239M as research, development & commercial milestones along with royalties on sales of the therapies
  • The companies collaborated for the development of therapies to treat DM1
  • The companies will collaborate their expertise to advance the novel therapeutic solutions addressing the patients’ needs

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Business Wire

The post Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy first appeared on PharmaShots.

Roche Collaborate with Moderna to include SARS-CoV-2 Ab Test in COVID-19 Vaccine Trials

Shots:

  • Roche allied with Moderna to utilize the Elecsys anti-SARS-CoV-2 S Ab test in mRNA-1273 study. The collaboration will facilitate the quantitative measurement of SARS-CoV-2 Abs and help to establish a correlation b/w vaccine-induced protection and levels of anti-RBD Abs
  • The alliance follows US FDA’s EUA for the Elecsys anti-SARS-CoV-2 S Ab test. Moderna’s vaccine is in late-stage trials with 30,000+ participants, showed the efficacy of 94% in preventing COVID-19, and is designed to trigger an Ab response to proteins found on the coronavirus spike’s receptor-binding domain
  • Elecsys Anti-SARS-CoV-2 is an immunoassay for the qualitative, in vitro detection of Abs (including IgG) to SARS-CoV-2

Click here to­ read full press release/ article | Ref: Roche | Image: The Conversation

The post Roche Collaborate with Moderna to include SARS-CoV-2 Ab Test in COVID-19 Vaccine Trials first appeared on PharmaShots.

Roche Collaborate with Moderna to include SARS-CoV-2 Ab Test in COVID-19 Vaccine Trials

Shots:

  • Roche allied with Moderna to utilize the Elecsys anti-SARS-CoV-2 S Ab test in mRNA-1273 study. The collaboration will facilitate the quantitative measurement of SARS-CoV-2 Abs and help to establish a correlation b/w vaccine-induced protection and levels of anti-RBD Abs
  • The alliance follows US FDA’s EUA for the Elecsys anti-SARS-CoV-2 S Ab test. Moderna’s vaccine is in late-stage trials with 30,000+ participants, showed the efficacy of 94% in preventing COVID-19, and is designed to trigger an Ab response to proteins found on the coronavirus spike’s receptor-binding domain
  • Elecsys Anti-SARS-CoV-2 is an immunoassay for the qualitative, in vitro detection of Abs (including IgG) to SARS-CoV-2

Click here to­ read full press release/ article | Ref: Roche | Image: The Conversation

The post Roche Collaborate with Moderna to include SARS-CoV-2 Ab Test in COVID-19 Vaccine Trials first appeared on PharmaShots.

Regeneron Collaborates with Penn to Explore Intranasal Delivery of COVID-19 Ab Cocktail via Gene Therapy Platform

Shots:

  • Penn allied with Regeneron to investigate Ab cocktail (casirivimab & imdevimab) to prevent COVID-19 infection when delivering intranasally via AAV vectors
  • The collaboration b/w Wilson and Penn’s GTP and Regeneron will have two phases. The first phase will include the validation of the effectiveness of Abs delivered via AAV in a large animal model challenge study. If successful, the research team will complete studies to support the filing of IND to the FDA
  • Regeneron’s Ab cocktail (casirivimab & imdevimab) is studied in clinical trials for the prevention of COVID-19 and has received the US FDA’s EUA in certain high-risk patients with mild to mod. COVID-19

Click here ­to­ read full press release/ article | Ref: Penn Medicine | Image: LaingBuisson News

The post Regeneron Collaborates with Penn to Explore Intranasal Delivery of COVID-19 Ab Cocktail via Gene Therapy Platform first appeared on PharmaShots.

Microsoft Collaborates with Twist and Illumina to Advance Data Storage in DNA

Shots:

  • Microsoft enters collaboration with Illumina, Twist, and Western Digital to establish a roadmap for the industry towards the wider use of DNA data storage. These companies are the founding members of the alliance
  • Ten additional technology leaders join founding members to together advance industry roadmap, set the stage for widespread adoption of new long-term storage option
  • The alliance announced at the virtual Flash Memory Summit, focus to set technology & formatting standards with the goal of building interoperable commercial systems capable of housing the exponential amounts of data expected to be generated in the future

Click here­ to­ read full press release/ article | Ref: Businesswire | Image: DNA Stack

The post Microsoft Collaborates with Twist and Illumina to Advance Data Storage in DNA first appeared on PharmaShots.

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Shots:

  • The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US
  • The therapy is currently being evaluated in P-II study for hospitalized patients with moderate COVID-19 with anticipated P-III initiation in Q1’21, that explores the potential use in patients outside of the hospital setting. Additionally, AT-527 may be developed for post-exposure prophylactic settings
  • AT-527 is an investigational, oral, purine nucleotide prodrug that has demonstrated in antiviral activity against several enveloped single-stranded RNA virus, including human flavivirus and coronavirus

Click here ­to­ read full press release/ article | Ref: Roche | Image: The Times of Israel

The post Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19 first appeared on PharmaShots.

Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

Shots:

  • The companies collaborate for fast-track development of DNP-019 against COVID-19
  • The collaboration will expand Samsung’s CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing
  • Samsung has introduced its proprietary cell-line technology, S-CHOice, demonstrating improved titers up to two-fold and maintaining over 90% cell viability

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

The post Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19 first appeared on PharmaShots.

Roche Collaborates with Genesis Therapeutics for AI-Driven Drug Discovery

Shots:

  • Genesis to receive an up front and is eligible to receive pre/ clinical and regulatory milestones along with royalties on sales of approved drugs emerges from the collaboration
  • The collaboration leverages Genesis’ graph machine learning and drug discovery expertise to identify drug candidates for therapeutic targets across multiple disease areas
  • Genesis has developed Dynamic PotentialNet and other neural network algorithms, examining drug-target complexes as flexible, spatial graphs, with the advantage of superior potency and selectivity prediction uniquely toward novel, previously undruggable targets and characterized therapeutic targets

Click here ­to­ read full press release/ article | Ref: BusinessWire | Image: BusinessWire

The post Roche Collaborates with Genesis Therapeutics for AI-Driven Drug Discovery first appeared on PharmaShots.

Takeda Collaborates with Accenture and AWS to Transform into a Cloud-Based Company

Shots:

  • Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the company in moving 80% of its applications to the cloud and modernizing its research tools
  • The transition of Takeda’s applications to the cloud will enable the company to remove non-differentiating technology and create a scalable architecture. The collaboration will leverage cloud and data-driven insights to accelerate drug development, increase operational agility, reduce technology costs, and develop the workforce of the future
  • Additionally, the collaboration with Accenture and AWS has already helped the Takeda to use the cloud in launching a clinical trial acceleration and secure data-sharing platform for the COVID R&D Alliance in <5days. The COVID R&D Alliance is a consortium comprising 20 companies, including Takeda, Amgen, and AbbVie to study and identify the potential of COVID-19 therapies

    Click here to­ read the full press release/ article | Ref: Takeda | Image: Enterprise Talk

The post Takeda Collaborates with Accenture and AWS to Transform into a Cloud-Based Company first appeared on PharmaShots.

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease

Shots:

  • Arrowhead to receive ~$300M up front, ~$740M as development, regulatory and commercial milestones and is eligible to receive royalties of 20-25% on net sales
  • If approved, the companies will co-develop ARO-AAT and co-commercialize it in the US, under 50/50 profit sharing structure. Additionally, Takeda will lead the global commercialization strategy and get an exclusive license to commercialize the therapy outside the US
  • ARO-AAT is designed to knock down the hepatic production of the Z-AAT protein and is potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD

    Click here ­to­ read full press release/ article | Ref: Takeda | Image: Technology Networks

The post Takeda Signs ~B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease first appeared on PharmaShots.

Takeda Collaborates with Engitix to Target Fibrotic Liver Diseases

Shots:

  • Engitix to receive up front with additional payments based on the confirmation and functional validation of selected targets and is eligible to receive $500M as preclinical, development, regulatory and commercial milestones along with royalties on sales of therapies
  • Takeda to get the exclusive rights to develop and commercialize the candidate emerges from the collaboration. The companies will validate the targets and preclinical development of therapeutics in liver fibrosis
  • The agreement will focus on developing novel therapies for advanced fibrotic liver diseases, including NASH. The collaboration integrates Engitix’s ECM platform with Takeda’s expertise in gastroenterology R&D and commercialization

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Ali Miller RD

Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic Kidney Disease

Shots:

  • Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies
  • The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on medical and molecular data sets of thousands of CKD patients
  • The collaboration allows Novo Nordisk to expand its portfolio beyond diabetes targeting the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: Novo Nordisk | Image: GMP News

Regeneron Collaborates with Roche to Improve the Global Supply of REGN-COV2 Against COVID-19

Shots:

  • The two global companies collaborated to develop, manufacture, and distribute REGN-COV2 across the globe. The agreement is expected to increase the supply of REGN-COV2 to at least 3.5 times the current capacity with the potential for expanding it further
  • Regeneron will lead the distribution in the US while Roche will be responsible for the distribution outside the US, both will bear distribution expenses in their designated territories. Each partner will dedicate a manufacturing capacity to REGN-COV2 every year while the collaborators have started the technology transfer process
  • The partners will jointly fund and execute the ongoing P-III prevention and P-I healthy volunteers safety studies as well as additional global studies to assess the potential for REGN-COV2 against COVID-19. Additionally, Roche will solely responsible for the initial EMA’s approval or conducting any additional studies required for approval outside the US

Click here ­to­ read full press release/ article | Ref: Roche| Image: StraitTimes

AstraZeneca Collaborates with mAbxience to Produce COVID-19 Vaccine in Latin America

Shots:

  • mAbxience will produce ~200M + doses of AZD1222 and will supply it to all Latin American countries, except Brazil
  • The company will produce API in its facility located in Garín (Argentina) and will send it to Mexico to complete the production and filling process. AstraZeneca will transfer its technology to the Garín plant shortly, allowing the facility to produce the vaccine in the coming months
  • AstraZeneca’s AZD1222 has demonstrated robust immune response in its P-I & II studies, being evaluated in P-III study with its expected completion in the coming months. The vaccine is expected to be available in the H1’21, upon completion of the P-III trial and approval

Click here ­to­ read full press release/ article | Ref: mAbxience | Image: Thailand Medical News

Related News: AstraZeneca to Initiate Production of its COVID-19 Vaccine Early in 2021

Novavax Collaborates with UK Government to Supply 60M Doses of NVX-CoV2373 to Combat COVID-19

Shots:

  • Novavax will supply ~60M doses of its COVID-19 vaccine to the UK government for P-III study evaluating the efficacy of NVX-CoV2373 in ~9,000 adults aged 18-85yrs. in the UK. The trial is expected to initiate in Q3’20
  • Novavax will expand its collaboration with FUJIFILM Diosynth, which will manufacture the antigen component of NVX-CoV2373 from its Billingham, Stockton-on-Tees site in the UK, in addition to its sites in NC and Texas in the US
  • The FUJIFILM Diosynth site in the UK is expected to produce up to 180M doses annually, which boosts the global supply of NVX-CoV2373 for additional markets. NVX‑CoV2373 elicited robust Ab responses superior to seen in human convalescent sera in P-I/II clinical study while P-II study is expected to begin in Aug’2020

Click here to­ read full press release/ article | Ref: Novavax | Image: Reuters

Strata Oncology Collaborates with Mirati Therapeutics to Broaden Enrollment in Clinical Trial of MRTX849 for Patients with Advanced Solid Tumors

Shots:

  • The multiple expansion cohort will assess the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors harboring a KRAS G12C mutation
  • Strata Oncology will identify patients to be considered for enrollment into Mirati’s P-I/II study. The Strata Trial provides tumor molecular profiling for patients with advanced cancer paired with a portfolio of biomarker-guided clinical trials
  • Strata Oncology utilizes StrataNGS which is a molecular profiling test optimized for performance on tumor tissue samples as small as 0.5mm2 surface area. MRTX849 is a novel KRAS G12C selective inhibitor

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Strata Oncology

Roche Collaborates with Celleron Therapeutics for Emactuzumab to Treat Patients with Tenosynovial Giant Cell Tumor

Shots:

  • Celleron will receive an exclusive global right for the clinical development, manufacturing, and commercialization of emactuzumab (formerly RG7155 and RO5509554). The companies expect the closing of an agreement by the end of 2020
  • 86% of TGCT patients treated with emactuzumab responded to the drug, with 68% of people experiencing a PR within 6 weeks of starting the treatment. The license agreement demonstrated Celleron’s dedication to the development of cancer medicine and its transformational potential for patients inflicted with cancer
  • Emactuzumab (RG7155) is an IgG1 mAb, designed to target and deplete macrophages in the tumor tissue.  The therapy targets TAMs by binding to CSF-1R on the cell surface and blocking its activation by CSF-1

Click here ­to­ read full press release/ article | Ref: Celleron Therapeutics | Image: PharmaShots

Sarepta Therapeutics Collaborates with University of Florida to Accelerate the Development of Therapies for Rare Genetic Diseases

Shots:

  • Sarepta to fund four research programs at the UF and will get an exclusive option to develop any new therapeutic compounds resulting from the funded research programs.
  • The projects include exploratory research in novel gene therapy vectors, next-generation capsids, and gene editing technologies along with new therapeutic areas in degenerative genetic diseases
  • The focus of the collaboration is to foster early relationships with experts and accelerate the scientific advancements leading to the development of transformational precision genetic medicines targeting the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: Sarepta Therapeutics | Image: CNBC

AstraZeneca Collaborates with Daiichi Sankyo to Evaluate the Combination of Patritumab Deruxtecan (U3-1402) + Tagrisso for EGFR-Mutated Non-Small Cell Lung Cancer

Shots:

  • Daiichi Sankyo to conduct two-part P-I study assessing U3-1402+ Tagrisso as both a 1L and 2L dual regimen in patients with advanced or mNSCLC with an EGFR exon 19 deletion or L858R mutation
  • The dose-escalation part will assess the safety & tolerability of different dosing combinations of dual regimen to determine the recommended dose while the second part of the study (dose expansion) will include a 1L and 2L cohort to further evaluate the anti-tumor activity and safety of the regimen
  • In the 1L cohort, patients will receive dual regimens and patients in the 2L cohort will be randomized in a ratio (1:1) to receive treatment with U3-1402 as monothx. or in combination with Tagrisso. 258 patients will be enrolled in the study, which will be conducted in NA, EU, and Asia including Japan

Click here to­ read full press release/ article | Ref: Daiichi Sankyo  | Image: StraitTimes




AstraZeneca Collaborates with Eko to Advance the Digital Health Tools for the Diagnosis of CV Diseases

Shots:

  • The two companies collaborated to facilitate the development of digital health tools for the earlier screening of cardiovascular diseases, including HF
  • AstraZeneca and Eko will accelerate the development of Eko algorithms, enhancing clinical trials with Eko technology, and potentially building new HF detection solutions. The agreement allows the companies to harness the potential to improve access to individualized care and generate better patient outcomes
  • In Dec’2019, Eko has received the US FDA’s BT designation for a novel ECG-based algorithm that can identify reduced LVEF. If approved, the algorithm will be compatible with the DUO, Eko’s handheld stethoscope, and ECG device

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Physician Practice




Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases

Shots:

  • The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts
  • Quantro will exploit its functional-genetic and transcriptomic technologies addressing the undruggable targets while Evotec will provide its hit identification services for Quantro’s anti-tumor projects
  • Additionally, Evotec joins Boehringer Ingelheim Venture Fund as seed investor in Quantro and acquired equal minority stakes in Quantro

Click here to read full press release/ article | Ref: Evotec | Image: Evotec




Biocon Collaborates with Voluntis on Digital Therapeutics for Insulins

Shots:

  • The two companies collaborated to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The collaboration allows Biocon to offer Insulia to T2D patients across several markets globally
  • Biocon aspires to reimagine the patient ecosystem by developing a technology-dependent operating model enabling personalization of care, thus going beyond the product to reduce both the cost of the drug as well as the cost of administering the drug
  • Insulia is the US FDA cleared and CE-marked digital therapeutic with regulatory clearance to provide automated titration recommendations for all types of basal insulins. Biocon is extending the Insulia platform to its complete range of insulin products, including Recombinant Human Insulin, Insulin Glargine and Insulin Aspart, creating a digital therapeutics portfolio for patients

Click here to read full press release/ article | Ref: Biocon | Image: Twitter




Roche Collaborates with Jnana Therapeutics to Discover Novel Therapies to Treat Immune-Mediated and Neurological Diseases

Shots:

  • Jnana to receive $40M upfront payment in cash and is eligible to get ~$1B as research funding, preclinical, development, and commercialization milestone along with royalties on sales of the therapies
  • The partners will work on the discovery and preclinical development of therapies targeting key regulators of cellular metabolism to treat across immunology and neuroscience while Roche will further develop and commercialize the therapies exclusively
  • The collaboration leverages Jnana’s RAPID platform designed to overcome the challenges of directly targeting SLC transporters. The RAPID platform is a cell-based platform that can be used to screen small molecule libraries to identify novel modulators of SLC transporter

Click here to read full press release/ article | Ref: Businesswire | Image: Twitter




MSD Collaborates with Novocure to Evaluate Tumor Treating Fields Together with Keytruda (pembrolizumab) in Non-Small Cell Lung Cancer

Shots:

  • The companies plan to conduct a P-II pilot study of tumor treating fields concomitant with Keytryda for 1L treatment of intrathoracic advanced/ metastatic PD-L1+ NSCLC. The study will enroll ~66 patients with its anticipated initiation in H2’20
  • The 1EPs od the study will be ORR while the 2EPs include OS, PFS, [email protected], one-year survival rate, DoR, disease control rate @18wks. and safety
  • Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing cancer cells to die and causes minimal damage to healthy cell

Click here to read full press release/ article | Ref: PRNewswire | Image: MedPage Today




NCCN Collaborates with Pfizer to Explore Adoption of Biosimilars in Oncology

Shots:

  • NCCN and Pfizer have issued an open RFP that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology
  • The RFP supports approaches to improve the processes related to biosimilar adoption in oncology. Letters of Intent are welcome from academic or community centers, patient advocacy groups and HCPs organizations in the US and are due on Sept 09, 2020
  • The NCCN ORP will boost up the discovery that improves the lives of people with cancer and supports preclinical, translational, clinical research and quality improvement projects in oncology

Click here to read full press release/ article | Ref: PRNewswire | Image: NCCN